Europe has long wanted Canada to match its longer patent protection for pharmaceutical drugs. It appears that Canada has agreed to extend patents by two years for drugs that are subject to lengthy reviews. Canadian provinces, which deliver health care under Canada’s public system, have demanded compensation for any increased drug costs.